TuHURA Biosciences (NASDAQ:HURA - Get Free Report) will likely be releasing its earnings data before the market opens on Tuesday, May 13th. Analysts expect TuHURA Biosciences to post earnings of ($0.14) per share for the quarter.
TuHURA Biosciences Stock Up 1.0 %
Shares of HURA stock traded up $0.04 during trading hours on Friday, reaching $3.97. The company had a trading volume of 90,740 shares, compared to its average volume of 252,910. TuHURA Biosciences has a 1-year low of $1.80 and a 1-year high of $7.93. The firm's 50 day simple moving average is $3.50.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in TuHURA Biosciences stock. Bank of America Corp DE bought a new position in shares of TuHURA Biosciences (NASDAQ:HURA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 14,314 shares of the company's stock, valued at approximately $59,000. Institutional investors and hedge funds own 0.62% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright decreased their price target on shares of TuHURA Biosciences from $13.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, April 3rd.
Get Our Latest Research Report on HURA
TuHURA Biosciences Company Profile
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
See Also

Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.